Why You Shouldn’t Let Royal Bank Of Scotland Group plc Look After Your Money


It was dubbed “the worst banking acquisition of all time”.

Sir Fred Goodwin led a series of acquisitions (including the purchase of NatWest) that turned the Royal Bank of Scotland Group (LSE: RBS) (NYSE: RBS.US) into an international banking giant. It all ended abruptly though with the £70 billion purchase of ABN AMRO. Not only was that deal structured poorly (certainly not in favour of RBS), but its timing (on the eve of the crisis), couldn’t have been much worse. Over a matter of months, RBS’s share price fell from over £6 pounds to 10p.

The prodigal son had to return home. It was bailed out by the state. It’s now 81% owned by the UK government.

So, given all of that, can we now bank on an RBS turnaround? Let’s look at the three C’s of banking.


The best news about RBS’s bottom line is that it’s seemingly improving. That is, back in May it proudly announced a big jump in its first quarter net profit. It trebled its earnings to £1.2 billion. According to Reuters it was just the 6th time the bank had produced a quarterly profit since it was bailed out. Analysts have pointed to the bank’s better handle on costs, and reduced losses from bad loans, as the reasons the bank’s pushed back into the black.

It’s also good to see the bank’s core business improving. Its net interest margin for the first half rose 20 basis points to 2.17%. That’s moving up towards Barclays’ NIM at 2.96% (up 8bps on its previous result).

So there are a few green shoots coming through — but some investors remain shy. The stock’s price to book ratio is just 0.6. Any decent banking analyst will tell you that’s either a really good sign, or an ominous sign.


RBs has a few skeletons in the closet.

In 2013 RBS was fined £390 million for Libor rigging. This coming from a bank that had been bailed out (and is now majority owned) by the taxpayer. That calls for more than just a good spanking. The bank’s also been done for the miss-selling of home loans in the U.S..


So the big news  is that chairman, Sir Philip Hampton, is moving to GlaxoSmithKline. The search for a new skipper is under way, but whoever it is, he or she will need to have a strong handle on negotiating with the government — given Treasury’s hold over the bank. This is an awkward issue for the bank.

Looking at its recent strategic plays: I’m not overjoyed by its recent stumble in the U.S.. RBS originally wanted to sell Citizens for between $23 (£14) and $25 a share but the initial public offering was priced at just $21.50. RBS will pocket around $2 billion less than hoped for as a result. It’s my understanding that RBS will look to offload the rest of the bank by 2016. Now analysts say the sale was a response to the government’s and regulators’ call for RBS to focus on lending to U.K. customers and increase its capital strength. See this is what happens when you still ‘live with your folks’ — you can’t make grown-up decisions.

Bonuses are another pain in the bum for the bank. Labour’s been crying foul that bankers on multi-million pound salaries are getting paid million dollar bonuses. Of course the tax payer foots that bill. Bonuses have already been cut by around 85% (yes they were that high to begin with) but they could go down further. They’re certainly not going to rise, putting up enormous barriers for the firm to attract the best talent in The City.

The bank says it’s doing just fine. It’s even confident it’ll achieve a Tier 1 capital ratio (a key measure of a bank’s financial strength) of 11% by the end of 2015. That’s noteworthy.

So yes the bank’s on track, but it hasn’t yet ‘recovered’ from the financial crisis of 2008/2009. As an indicator, the bank’s share price remains well below the 500p level where the taxpayer breaks even on its £45 billion stake in the bank.

I’ll confidently step onto the ship when all the bail water has returned to the ocean. No need to take unnecessary risks right now.

Choosing the right bank to invest in can be tough. Once upon a time they were considered 'buy and hold' stocks. Now you have to consider the regulatory environment, how much capital they have, their income growth outlook and what management are up to. Well, the Fools have come up with a short guide to help you out with all this.

We call it the Fools Guide To Investing In Banks. Consider it your tool-kit for building a portfolio of banking stocks -- or maybe you just want to use it to choose the best individual bank stock. You'll find once you get a handle on it, that choosing the right stock will become an exciting prospect, because you'll be confident you're making a good decision. Click here for your free report. There's no catch here. It's literally free of charge.

The Motley Fool has recommended shares in GlaxoSmithKline.